Prevalence of Tick-borne Encephalitis in the Pediatric Population Treated at the HUS and Characterization of Confirmed Pediatric Cases

NCT05607394 | Unknown

• 1 other identifier: 8725
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

Tick-borne encephalitis (TBE) is a zoonosis mainly transmitted to humans by the bite of ticks of the genus Ixodes and, to a lesser extent, by the consumption of contaminated and unpasteurized dairy products. During the last decade, the epidemiology of this arbovirosis has changed profoundly with the discovery of new human cases and/or new areas of circulation of tick-borne encephalitis virus (TBEV) throughout Europe and particularly in France. Historically, Alsace is the main endemic area for this pathology in France. The pathology is notifiable since June 2021 in France. Although TBEV infection in children seems to lead to a milder clinical presentation, data are much less abundant than in adults and only a few cases reported in infants under 1 year old have been published. Data from the most recent ECDC Annual Epidemiological Report on TBE (2019) showed incidence rates of approximately 0.2 and 0.5 per 100,000 population in patients younger than 5 and 15 years, respectively. However, several observations may moderate and challenge both the low incidence rate and the less severe clinical presentation reported in children

Conditions

Tick-borne Encephalitis

Keywords

Tick-borne encephalitis (TBE); Genus Ixodes; TBEV infection; TBEV infection in children; Prevalence of TBE

Outcome Measures

Primary Outcomes (1)

• Determining the prevalence of TBE in pediatric patients (aged 0 to 15 years)

  2 years after infection with tick-borne encephalitis (TBE)

Eligibility Criteria

• Age: 0 Years - 16 Years
• Sex: all
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Minor subject (≤ 16 years) having had a CSF sample taken as part of care, without infectious (other than TBE) or non-infectious etiology diagnosed.

You may qualify if:

• Minor subject (≤ 16 years)
• hospitalized at the University Hospital of Strasbourg between 01/01/2020 and 31/12/2022
• having had a CSF sample taken as part of care, without infectious (other than TBE) or non-infectious etiology diagnosed
• whose parental authority holders have already given their consent for their child's biological resources to be kept in the "Microbiology" biocollection and reused for scientific research purposes.

You may not qualify if:

• Patient or parental authority holders who have expressed their opposition to participate in the study
• Any person, male or female, over 16 years of age,
• or any person, male or female, under 16 years of age, treated at the University Hospitals of Strasbourg from January 2020 to December 2022, who has had a CSF sample taken as part of their care, for which a non-infectious etiology or an infectious etiology other than TBE has been diagnosed.
• Impossible to give the subject informed information (difficulties in understanding the subject, ...)

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service Laboratoire de Virologie - PTM - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

Encephalitis, Tick-Borne

Condition Hierarchy (Ancestors)

Encephalitis, Arbovirus; Encephalitis, Viral; Central Nervous System Viral Diseases; Central Nervous System Infections; Infections; Infectious Encephalitis; Arbovirus Infections; Vector Borne Diseases; Tick-Borne Diseases; Virus Diseases; RNA Virus Infections; Flavivirus Infections; Flaviviridae Infections; Encephalitis; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neuroinflammatory Diseases

Central Study Contacts

Aurélie Velay-Rusch, MD

CONTACT

33 3 69 55 14 40; aurelie.velay@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 31, 2022
• First Posted: November 7, 2022
• Study Start: October 24, 2022
• Primary Completion: August 24, 2023
• Study Completion: October 24, 2023
• Last Updated: November 14, 2022

Record last verified: 2022-10

Locations

FR (1)